Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

June 2024: The Food and Drug Administration has given accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) in combination with cetuximab for adults who have KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as confirmed by an FDA-approved test, and who have previously undergone treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

The evaluation of efficacy was conducted in KRYSTAL-1, which is a trial including multiple centers and a single-arm expansion cohort. Patients who were considered suitable had to have locally advanced or metastatic colorectal cancer (CRC) with a specific KRAS G12C mutation. They must have received prior treatment with the chemotherapeutic drugs fluoropyrimidine, oxaliplatin, and irinotecan, as well as a VEGF inhibitor, if they satisfied the criteria.

Patients received adagrasib at a dosage of 600 mg twice a day, along with cetuximab given either every two weeks at a rate of 500 mg/m2 or weekly with an initial dose of 400 mg/m2 followed by 250 mg/m2. Regular evaluations of the tumor were conducted at 6-week intervals. Discontinuation of adagrasib necessitated discontinuation of cetuximab, however, patients were allowed to continue adagrasib if cetuximab was withdrawn.

The confirmed overall response rate (ORR) and the duration of response (DOR) were the two main ways to measure how well the treatment worked. They underwent a neutral, independent central review and were based on the RECIST v1.1 criteria.

Among the 94 patients who participated in the study, the overall response rate (ORR) was 34%, with a 95% confidence interval (CI) ranging from 25% to 45%. All of the responses seen were partial responses. The median duration of response (DOR) was 5.8 months, with a 95% CI ranging from 4.2 to 7.6 months. 31% of the patients who responded had a duration of response (DOR) of 6 months or more.

The predominant side effects (≥20%) included rash, nausea, diarrhea, vomiting, fatigue, musculoskeletal discomfort, hepatotoxicity, headache, dry skin, stomach pain, decreased appetite, edema, anemia, cough, disorientation, constipation, and peripheral neuropathy.

The suggested dosage for adagrasib is 600 mg administered orally twice a day until there is evidence of disease progression or the presence of adverse effects that are deemed intolerable. Consult the Cetuximab prescribing information for more details regarding the recommended dosage of Cetuximab.

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Datopotamab deruxtecan-dlnk is approved by the USFDA for EGFR-mutated non-small cell lung cancer
• Susan Hau

  https://cancerfax.com/author/susan/

  PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy
• Susan Hau

  https://cancerfax.com/author/susan/

  Neoadjuvant and adjuvant pembrolizumab is approved by the USFDA for resectable locally advanced head and neck squamous cell carcinoma
• Susan Hau

  https://cancerfax.com/author/susan/

  Taletrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer

• Comments Closed
• June 22nd, 2024